Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants

Natasha B. Halasa, Samantha M. Olson, Mary A. Staat, Margaret M. Newhams, Ashley M. Price, Pia S. Pannaraj, Julie A. Boom, Leila C. Sahni, Kathleen Chiotos, Melissa A. Cameron, Katherine E. Bline, Charlotte V. Hobbs, Aline B. Maddux, Bria M. Coates, Kelly N. Michelson, Sabrina M. Heidemann, Katherine Irby, Ryan A. Nofziger, Elizabeth H. Mack, Laura SmallcombStephanie P. Schwartz, Tracie C. Walker, Shira J. Gertz, Jennifer E. Schuster, Satoshi Kamidani, Keiko M. Tarquinio, Samina S. Bhumbra, Mia Maamari, Janet R. Hume, Hillary Crandall, Emily R. Levy, Matt S. Zinter, Tamara T. Bradford, Heidi R. Flori, Melissa L. Cullimore, Michele Kong, Natalie Z. Cvijanovich, Suzanne M. Gilboa, Kara N. Polen, Angela P. Campbell, Adrienne G. Randolph, Manish M. Patel

Research output: Contribution to journalArticlepeer-review

100 Scopus citations


Infants younger than 6 months of age are at high risk for complications of coronavirus disease 2019 (Covid-19) and are not eligible for vaccination. Transplacental transfer of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after maternal Covid-19 vaccination may confer protection against Covid-19 in infants. METHODS We used a case–control test-negative design to assess the effectiveness of maternal vaccination during pregnancy against hospitalization for Covid-19 among infants younger than 6 months of age. Between July 1, 2021, and March 8, 2022, we enrolled infants hospitalized for Covid-19 (case infants) and infants hospitalized without Covid-19 (control infants) at 30 hospitals in 22 states. We estimated vaccine effectiveness by comparing the odds of full maternal vaccination (two doses of mRNA vaccine) among case infants and control infants during circulation of the B.1.617.2 (delta) variant (July 1, 2021, to December 18, 2021) and the B.1.1.259 (omicron) variant (December 19, 2021, to March 8, 2022). RESULTS A total of 537 case infants (181 of whom had been admitted to a hospital during the delta period and 356 during the omicron period; median age, 2 months) and 512 control infants were enrolled and included in the analyses; 16% of the case infants and 29% of the control infants had been born to mothers who had been fully vaccinated against Covid-19 during pregnancy. Among the case infants, 113 (21%) received intensive care (64 [12%] received mechanical ventilation or vasoactive infusions). Two case infants died from Covid-19; neither infant’s mother had been vaccinated during pregnancy. The effectiveness of maternal vaccination against hospitalization for Covid-19 among infants was 52% (95% confidence interval [CI], 33 to 65) overall, 80% (95% CI, 60 to 90) during the delta period, and 38% (95% CI, 8 to 58) during the omicron period. Effectiveness was 69% (95% CI, 50 to 80) when maternal vaccination occurred after 20 weeks of pregnancy and 38% (95% CI, 3 to 60) during the first 20 weeks of pregnancy. CONCLUSIONS Maternal vaccination with two doses of mRNA vaccine was associated with a reduced risk of hospitalization for Covid-19, including for critical illness, among infants younger than 6 months of age.

Original languageEnglish (US)
Pages (from-to)109-119
Number of pages11
JournalNew England Journal of Medicine
Issue number2
StatePublished - Jul 14 2022
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants'. Together they form a unique fingerprint.

Cite this